Skip to main content
Ann Mullally, MD, Oncology, Boston, MA, Brigham and Women's Hospital

AnnMarieMullallyMD

Oncology • Boston, MA

Hematologic Oncology

Associate Professor at Harvard Medical School

Join to view full profile

Dr. Mullally is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Mullally's full profile

Already have an account?

  • Office

    77 Avenue Louis Pasteur
    Harvard Institutes of Medicine Building, Room 738
    Boston, MA 02115
    Phone+1 617-525-4980
  • Is this information wrong?

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2006 - 2010
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 2002 - 2005
  • University College of Dublin National Univ SOM
    University College of Dublin National Univ SOMClass of 1999

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2005 - 2024
  • American Board of Internal Medicine Hematology

Publications & Presentations

PubMed

Abstracts/Posters

  • Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response
    Ann Mullally, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera
    Ann Mullally, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Zinc-Dependent Homomultimerization of Mutant Calreticulin Is Required for MPN Pathogenesis
    Ann Mullally, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Friday Scientific Workshop on the Interplay Between Coagulation and Malignancy 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • MPN Tumor Board: Application of Novel Agents for the Treatment of Polycythemia Vera and Myelofibrosis 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • As If Myeloproliferative Neoplasms Weren't Already Challenging Enough 
    60th American Society of Hematology Annual Meeting - 12/2/2018
  • Join now to see all

Press Mentions

  • Harvard Researchers Discover Some Cancers May Originate Decades Earlier Than Previously Believed
    Harvard Researchers Discover Some Cancers May Originate Decades Earlier Than Previously BelievedMarch 12th, 2021
  • Original Error: Retracing the History of the Mutation That Gave Rise to Cancer Decades Later
    Original Error: Retracing the History of the Mutation That Gave Rise to Cancer Decades LaterMarch 10th, 2021
  • Splicing Factor YBX1 Mediates Persistence of JAK2-Mutated Neoplasms
    Splicing Factor YBX1 Mediates Persistence of JAK2-Mutated NeoplasmsNovember 25th, 2020
  • Join now to see all

Hospital Affiliations

Dr. Ann Mullally, Dr. Ann Mullally, MD, Dr. A Mullally, Dr. Ann Marie Mullally